Treating Advanced Lymphoma

Last Modified: October 2, 2003

Share article

Conference Dates: October 29, 2003
Conference Location: Penn Tower Bridge Level Conference Room

Sponsoring Group: Abramson Cancer Center and Leukemia-Lymphoma Society

Topics Covered: "Latest Developments in Research and Clinical Applications" "The Use of Radioimmunotherapy" "Living Well and Coping with Lymphoma"

Conference Objectives: Patient Education

Who Should Attend: Patients, friends and family members

Conference Agenda:

  • Stephen J. Schuster, M.D.
    Associate Professor of Medicine, Director, Lymphoma Program
  • Lisa H. Downs, MSN, CRNP
    Coordinator, Lymphoma Program
  • Karen Zatzarony, MSS, LSW
    Senior Patient Services Manager, Leukemia-Lymphoma Society

Registration Information: Jill Harrington LaMorie, MSW, LSW Patient Services Coordinator 215-349-8869

Conference Fees: Free/Parking Paid

Continuing Education: No

Bortezomib Combo Effective in Advanced Follicular Lymphoma

Aug 3, 2011 - Bortezomib, given in combination with rituximab, cyclophosphamide, vincristine, and prednisone, is feasible for treating patients with advanced-stage follicular lymphoma, and the combination of bortezomib, bendamustine, and rituximab is active in patients with follicular lymphoma who have received previous treatment, according to two studies published online Aug. 1 in the Journal of Clinical Oncology.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More